Macomics, The Macrophage-Based Drug Discovery Company, Secures £4.24M Expansion Financing, And Appoints Ceo, Cso And Vp Immunology
Jul 29, 2021•about 4 years ago
Amount Raised
£4.24 Million
Description
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.
FundzWatch™ Score
66
Medium Activity